Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3006427 | 0.94 | PTPN1 (0.46) | PTPN1PTPN2PTGER1CYP1A2MAOB | |
| SCHEMBL629845 | 0.94 | PTPN1 (0.46) | PTPN1PTPN2PTGER1CYP1A2MAOB | |
| SCHEMBL3005189 | 0.94 | PTPN1 (0.48) | PTPN1PTPN2MAOBMAPK14 | |
| SCHEMBL3006548 | 0.84 | LRRK2 (0.38) | PTPN1PTGER1CYP1A2HTR7HTR6 | |
| SCHEMBL629774 | 0.84 | PTPN1 (0.51) | PTPN1PTPN2CYP1A2MAOBALDH1A1 | |
| Potassium SCHEMBL629775 | 0.84 | PTPN1 (0.51) | PTPN1PTPN2CYP1A2MAOBALDH1A1 | |
| SCHEMBL12056127 | 0.83 | PTPN1 (0.50) | PTPN1PTPN2PTGER1HTR6MAOB | |
| SCHEMBL4643306 | 0.83 | PTPN1 (0.53) | PTPN1PTPN2PTGER1CYP1A2SLC6A4 | |
| Potassium SCHEMBL2998210 | 0.83 | PTPN1 (0.61) | PTPN1PTPN2MAOB | |
| SCHEMBL2998204 | 0.83 | PTPN1 (0.61) | PTPN1PTPN2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197744-A1 | Organic Compounds | BARNES DAVID | 2010-08-05 | — | — | US | disclosed |
| EP-2155704-A1 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148744-A1 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197744-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | PTPN1 25/4885PTPN2 10/4885PTGER1 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.